Rachel K. King
Independent DirectorMrs. Rachel K. King co-founded Glycomimetics, Inc. in 2003 and served as its Chief Executive Officer and its President since 2003 until August 6, 2021. She serves as Independent Director of Fulcrum Therapeutics, Inc since November 12, 2024. She has been an Independent Director of Novavax, Inc. since November 1, 2018. Mrs. King joined the Novavax Board in 2018. Mrs. King served as an Executive in Residence at New Enterprise Associates (NEA) from 2001 to 2003. She served as a Senior Vice President of Novartis Corporation from 1999 to 2001. She was Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis from 1996 to 1998. She served as an executive with Genetic Therapy, Inc. for several years. At GTI, Mrs. King held various roles, including serving as its Chief Executive Officer. Mrs. King previously worked at Alza Corporation, a pharmaceutical and medical systems company that was later acquired by Johnson & Johnson, as well as at Bain and Company, a management consulting firm. Mrs. King worked at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She serves as a Vice Chairman of Health Section at the Biotechnology Industry Organization (BIO). She serves as a Director of Biotechnology Innovation Organization since 2013 and served as its Interim President and Chief Executive Officer since November 2022. She has been a Director of Warp Drive Bio, LLC since July 2016. She serves on the Dean's Council of the Harvard School of Public Health and on the Board of Imagination Stage. She had been a Director of GlycoMimetics, Inc. since 2003 until February 21, 2025. She was Manager of Laboratory Operations atGenetic Therapy, Inc. from 1989 to 1993 and Vice President for Product Planning from 1993 to 1996 including early-stage development, initial public offering and acquisition by Novartis. She served as a Director of MDBio, Inc. She served as Chair of the Maryland Life Sciences Advisory Board from 2013 to 2015. She also serves on the Board of the University of Maryland BioPark. Mrs. King received her B.A. degree from Dartmouth College and her MBA degree from Harvard Business School.
Positions
- Company NameFulcrum Therapeutics, Inc.Stock CodeFULCPositionIndependent DirectorColleagues
- ACAlexander C. SapirCEO, President & Director
- KHKathryn HavilandIndependent Chair of the Board
- AAAlan A. MussoCFO, Treasurer & Principal Accounting Officer
- CGCurtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- BEBradley E. BernsteinFounder
- MRMichael R. GreenFounder
- JAJames Arthur GeraghtyIndependent Director
- KDKatina DortonIndependent Director
